Gallbladder metastases of breast cancer: from clinical-pathological patterns to diagnostic and therapeutic strategy

Clin Ter. 2011;162(5):451-6.

Abstract

Gallbladder metastasis of breast cancer are rare, particularly linked to lobular histotype and synchronous just in 1/4 cases. A review of the literature has been performed aimed to evidence the patterns of gallbladder metastases of breast cancer finding 15 cases to whom we added a 48 years old post-menopausal woman. 3 weeks after surgery for mixed ductal-lobular breast carcinoma she showed at the abdominal ultrasound, performed for staging, diffuse thickening of the gallbladder wall , coherent with a chronic cholecystitis and with the mild right-upper-abdominal pain that the patient complained in the last months. After laparoscopic cholecystectomy, the pathology report showed a metastatic lobular carcinoma of the breast. Two years later she presented with SNC metastases and died four months later. Lobular histotype is the most frequent breast neoplasm associated with gallbladder metastases. Usually metachronous, these metastases are sinchronous in 28% of cases. Symptoms are usually linked to coexisting acute or cronic cholecystitis. Rarely massive invasions lead to acute abdomen or jaundice. Imaging is rarely diagnostic for neoplasm. Our experience and data from literature lead to careful evaluate every anomaly observed in breast cancer patients. A careful evaluation of abdominal symptoms and of routine imaging examinations performed for staging and for treatment planning, could consent to detect and radically treat the metastases and appropriately assign the chemotherapy. Such approach can lead to discrete survival even in these unfortunate patients. Surgeons and gastroenterologists should be aware of the risk hidden behind apparently benign, mild diseases in such patients.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Aromatase Inhibitors / administration & dosage
  • Biomarkers, Tumor / analysis
  • Brain Neoplasms / secondary
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / radiotherapy
  • Breast Neoplasms / surgery
  • Carcinoma, Ductal, Breast / diagnosis
  • Carcinoma, Ductal, Breast / drug therapy
  • Carcinoma, Ductal, Breast / radiotherapy
  • Carcinoma, Ductal, Breast / secondary*
  • Carcinoma, Ductal, Breast / surgery
  • Carcinoma, Lobular / diagnosis
  • Carcinoma, Lobular / drug therapy
  • Carcinoma, Lobular / radiotherapy
  • Carcinoma, Lobular / secondary*
  • Carcinoma, Lobular / surgery
  • Chemotherapy, Adjuvant
  • Cholecystectomy, Laparoscopic
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Estrogens*
  • Fatal Outcome
  • Female
  • Gallbladder Neoplasms / diagnosis
  • Gallbladder Neoplasms / drug therapy
  • Gallbladder Neoplasms / secondary*
  • Gallbladder Neoplasms / surgery
  • Humans
  • Lymph Node Excision
  • Mastectomy, Segmental
  • Middle Aged
  • Neoplasms, Hormone-Dependent / diagnosis
  • Neoplasms, Hormone-Dependent / secondary*
  • Neoplasms, Hormone-Dependent / surgery
  • Paclitaxel / administration & dosage
  • Postmenopause
  • Progesterone*
  • Radiotherapy, Adjuvant

Substances

  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Biomarkers, Tumor
  • Estrogens
  • Progesterone
  • Doxorubicin
  • Cyclophosphamide
  • Paclitaxel